Observational studyCancer medicine2025

JMT103 versus Non-Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score-Matched Comparison.

Hairong Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.